The presence of metastasis is the most important prognostic indicator in patients with prostate carcinoma and is the predominant determinant of therapeutic choices. Current tools for detection of recurrence or metastasis are less than optimal. Recent clinical trials with radiolabeled monoclonal antibodies appear to provide more precise localization of prostate cancer in these clinical circumstances
Methods
Multicenter national trials of patients at relatively high risk for metastasis at diagnosis and patients with biochemical evidence of recurrence after prostatectomy underwent radioimmunoscintigraphy with capromab pendetide.
Results
Tissue confirmation of scan results demonstrated a 15-fold and 4-fold increase in sensitivity over computed tomography and magnetic resonance imaging, respectively, for newly diagnosed patients. Preliminary data have shown a 3- to 4-fold increase in durable complete response to radiation therapy in patients with biochemical failure following radical prostatectomy.
Conclusions
Patients at relatively high risk for metastasis at diagnosis and those with biochemical evidence of recurrence after prostatectomy may benefit from radioimmunoscintigraphy.
Get full access to this article
View all access options for this article.
References
1.
ParkerS.L., TongT., BoldenS.Cancer statistics, 1997. CA Cancer J Clin.1997; 47: 5–27.
2.
PartinA.W., YooJ., CarterH.B.The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol.1993; 150: 110–114.
3.
PartinA.W., PoundC.R., ClemensJ.Q.Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am.1993; 20: 713–725.
4.
PoundC.R., PartinA.W., EpsteinJ.I.Prostate-specific antigen after anatomic radical prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am.1997; 24: 395–406.
5.
GeeW.F., HoltgreweH.L., AlbertsenP.C.Practice trends in the diagnosis and management of prostate cancer in the United States. J Urol.1995; 154: 207–208.
6.
WassermanN.F., KapoorD.A., HildebrandtW.C.Transrectal US in evaluation of patients with radical prostatectomy. Part II. Transrectal US and biopsy findings in the presence of residual and early recurrent prostatic cancer. Radiology.1992; 185: 367–372.
7.
FosterL.S., JajodiaP., FournierG.Jr. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol.1993; 149: 1024–1028.
8.
BostwickD.G., GrahamS.D.Jr, NapalkovP.Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology.1993; 41: 403–411.
9.
ShinoharaK., ScardinoP.T., CarterS.S.Pathologic basis of the sonographic appearance of the normal and malignant prostate. Urol Clin North Am.1989; 16: 675–691.
10.
WrightG.L.Jr, HaleyC., BeckettM.L.Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol.1995; 1: 18–28.
11.
BabaianR.J., SayerJ., PodoloffD.A.Radioimmunoscintigraphy of pelvic lymph nodes with 111Indium-labeled monoclonal antibody CYT-356. J Urol.1994; 152: 1952–1955.
12.
KahnD., WilliamsR.D., SeldinD.W.Radioimmunoscintigraphy with 111Indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol.1994; 152: 1490–1495.
13.
McLaughlinA.P., SaltzsteinS.L., McCulloughD.L.Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. J Urol.1976; 115: 89–94.
PartinA.W., KattanM.W., SubongE.N.Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA.1997; 277: 1445–1451.
16.
LeeJ.K., McClennanB.L., StanleyR.J.Use of CT in evaluation of postcystectomy patients. AJR Am J Roentgenol.1981; 136: 483–487.
17.
FlaniganR.C., MohlerJ.L., KingC.T.Preoperative lymph node evaluation in prostate cancer patients who are surgical candidates: the role of lymphangiography and computerized tomography scanning with directed fine needle aspiration. J Urol.1985; 134: 84–87.
18.
PlattJ.F., BreeR.L., SchwabR.E.The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol.1987; 149: 315–318.
19.
FergusonJ.K., OesterlingJ.E.Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol Clin North Am.1994; 21: 677–685.
20.
OyenR.H., Van PoppelH.P., AmeyeF.E.Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology.1994; 190: 315–322.
21.
DavidV.MR imaging of the prostate and seminal vesicles. Magn Reson Imaging Clin N Am.1996; 4: 497–518.
22.
HallezJ.P.Single-stage total hysteroscopic myomectomies: indications, techniques, and results. Fertil Steril.1995; 63: 703–708.
23.
VassalloP., MateiC., HestonW.D.AMI-227 enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology.1994; 193: 501–506.
24.
BabaianR.J., SayerJ., PodoloffD.A.Radioimmunoscintigraphy of pelvic lymph nodes with 111Indium-labeled monoclonal antibody CYT-356. J Urol.1994; 152: 1952–1955.
25.
ManyakM.J., JavittM.C.The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Semin Urol Oncol.1998; 16: 145–152.
26.
OesterlingJ.E.Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am.1993; 20: 705–711.
27.
LightnerD.J., LangeP.H., ReddyP.K.Prostate specific antigen and local recurrence after radical prostatectomy. J Urol.1990; 144: 921–926.
28.
Abi-AadA.S., MacfarlaneM.T., SteinA.Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol.1992; 147: 952–955.
29.
NarayanP., HricakH.Imaging in prostate cancer. In: VogelzangN.J., ScardinoP.T., ShipleyW.U., CoffeyD.S., eds. Comprehensive Textbook of Genitourinary Oncology.Baltimore, MD: Williams and Wilkins; 1996: 723–733.
30.
WhiteS., HricakH., ForstnerR.Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology.1995; 195: 385–390.
31.
TakayamaT.K., LangeP.H.Radiation therapy for local recurrence of prostate cancer after radical prostatectomy. Urol Clin North Am.1994; 21: 687–700.
32.
SchieblerM.L., SchnallM.D., OutwaterE.MR imaging of mucinous adenocarcinoma of the prostate. J Comput Assist Tomogr.1992; 16: 493–494.
33.
BuonocoreE., HesemannC., PavlicekW.Clinical and in vitro magnetic resonance imaging of prostatic carcinoma. AJR Am J Roentgenol.1984; 143: 1267–1272.
34.
TempanyC.M., ZhouX., ZerhouniE.A.Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology.1994; 192: 47–54.
35.
KahnD., WilliamsR.D., HasemanM.K.Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol.1998; 16: 284–289.
